- Home
- ESLA vs EVAX Comparison
ESLA vs EVAX Comparison
Compare ESLA & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | EVAX |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.9M | 42.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ESLA | EVAX |
|---|---|---|
| Price | $1.99 | $5.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $16.00 | $12.33 |
| AVG Volume (30 Days) | ★ 243.3K | 99.2K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,650,000.00 |
| Revenue This Year | N/A | $128.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 132.17 |
| 52 Week Low | $0.73 | $1.20 |
| 52 Week High | $3.15 | $12.15 |
Technical Indicators
Market Signals| Indicator | ESLA | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 46.34 |
| Support Level | $1.52 | $5.03 |
| Resistance Level | $2.27 | $6.12 |
| Average True Range (ATR) | 0.31 | 0.45 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 59.04 | 32.46 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.